ArticleESMO open2018

Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer.

Masahito Kotaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.